Clinical trial
Pharmacokinetic Response to BPI in Burns
NCT00462904 · University of Texas Southwestern Medical Center, Other · Terminated
Key facts
| NCT number | NCT00462904 |
|---|---|
| Title | Pharmacokinetic Response to BPI in Burns |
| Official title | Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury. |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Burns |
| Intervention type | Drug |
| Interventions | BPI |
| Enrollment | 4 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 19, 2007 |
| Last update posted | Nov 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: